Items Tagged ‘RAD1901’

October 26, 2017

Radius Health Receives FDA Fast Track Designation for Elacestrant


The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for elacestrant, an investigational oral selective estrogen receptor down-regulator/degrader (SERD) as a treatment of women with ER+ and HER2- advanced or metastatic breast cancer. Fast Track designation is a process designed to facilitate the development and expedite the review of new therapies to […]

View full entry

Tags: Breast Cancer, Elacestrant, News, RAD1901